Main description:

Ovarian cancer remains one of the major causes of cancer mortality in women throughout the world with a 5-year survival rate of approximately 30 per cent for patients with advanced-stage disease. Over the last two decades, our understanding of the molecular and cellular biology of ovarian cancer has dramatically increased. Our main challenge in the next decade is to accelerate progress in the clinical management of ovarian cancer by translating research findings from ovarian cancer biology to clinical practice, such that we can improve the diagnosis and treatment of this disease. This involves not only the development of new biomarkers, drugs, and vaccines, but also their evaluation by means of trials that measure biological endpoints as well as clinical activity. Given the challenges and opportunities ahead of us, this is a particularly appropriate time to take stock of our current understanding of ovarian cancer and our ability to diagnose and treat the disease. The book identifies recent advances as well as the shortcomings of current practice, and places an emphasis on the latest translational studies.
"Ovarian Cancer: State of the Art" is authored by experts who have made significant contributions to ovarian cancer research in their specific field of interest, and provides a comprehensive, critical review of the rapidly expanding literature base.

Contents:

1) Molecular, cellular, and clinical biology. 2) Biomarkers for Ovarian Cancer. 3) Surgical Management. 4) Chemotherapy. 5) Molecular therapeutics in epithelial ovarian cancer. 6) Tumour immunology and immunotherapy. 7) Supportive Care.